Mesoblast Limited (MSB)

Welcome to InvestSMART

You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:

Sign Up Today Ľ it's FREE! Already a member? Login now!

General Information
Company Name: Mesoblast Limited
Stock Code: MSB
GICS Sub-Industry: Biotechnology
Market Cap ($M): 1,550
Equiv. Shares (M): 322

Current Price Data+
Current Price Open High Low Last Close Volume Price Movement
 $ 4.710 $ 4.780 $ 4.830 $ 4.710 $ 4.820 183,837 $ -0.110  -2.282 %

Current Broker Consensus Recommendation more
Recommendation: Buy (2)
Recommendation Date: 17th Sep 2014
Brokers Surveyed: 2

Company Overview

Business Description:
Mesoblast Limited (MSB) is an Australian company engaging in the development of biologic products for the broad field of regenerative medicine. The key focus is on research and development of adult Mesenchymal Precursor Cells (MPCs), Mesenchymal Stem Cells (MSCs), Dental Pulp cells and Adipose cells. Its intellectual property covers a range of applications in key markets including the United States, Europe, Japan and China.

Strategy Analysis:
MSB is developing a proprietary stem cell technology for the treatment of orthopaedic conditions such as bone fractures, degenerated knee cartilage and vertebral disc degeneration. Through an investment in and subsequent merger with Angioblast Systems, Inc. MSB is also developing stem cell treatments for cardiac and vascular diseases, and other degenerative conditions. MSB's strategy is to maximise shareholder value through both corporate partnerships and the rapid and successful completion of pre-clinical and clinical milestones to commercialise the technology. The firm already has TGA approval to manufacture and distribute patient-specific adult stem cell products to hospitals and physicians across Australia; this is the first culture-expanded adult stem cell product to receive manufacturing approval anywhere in the world. Mesoblast reported a net loss of $27.79m for the half-year ended 31 December 2012 (31 Dec 2011: $17.6m). The increased loss was driven by a reduction in revenue from continuing operations and other income of $4.3m and an increase in expenses from continuing operations of $5.9m. Revenues from ordinary activities were $14.73m, down 22% from the same period last year. Diluted EPS was (9.69) cents compared to (15.52) cents last year. The net operating cash outflow was $30.52m compared to an outflow of $36.89m in the pcp. No dividend was declared. In the second half of the financial year, the Company expects to continue to report on clinical outcomes from a number of Phase 2 programs and to initiate new programs in line with the overall corporate strategy.

Financial Summary
Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2016  F -101.8 -29.7 -3.7 -16.3 0.0 0.0 0.0
2015  F -101.6 -30.8 -9.4 -15.7 0.0 0.0 0.0
2014  A -108.5 -34.0 14.7 -16.3 0.0 0.0 0.0
Source: Morningstar analyst estimates.

Peer Comparison
EPS Growth (%) P/E (%) Dividend Yield (%)
Company Mkt Cap 2014 A 2015 F 2016 F 2014 A 2015 F 2016 F 2014 A 2015 F 2016 F
Bionomics (BNO) $240 M -- 6.3247 0.3032 74.6753 10.1950 7.8231 0.00 0.00 0.00
CSL (CSL) $34,348 M 0.0899 0.1803 0.1256 25.3334 21.4633 19.0678 1.66 1.97 2.16
Mesoblast (MSB) $1,579 M -- -- -- -- -- -- 0.00 0.00 0.00
Starpharma (SPL) $202 M -- -- -0.9512 -- 8.6691 177.5000 0.00 0.00 0.00
Sirtex Medical (SRX) $1,274 M 0.2906 0.5107 0.3715 54.6005 36.1436 26.3527 0.00 0.80 1.33

Market Comparison
Earnings P/E Ratio P/B Ratio P/E Growth P/S Ratio
MSB -- -- 2.67 -- 93.8
Market 0.94 15.6 1.28 1.74 1.56
Sector 0.68 22.0 3.21 1.35 8.35

Name Position Start Date
Dr Silviu Itescu Executive Director 08 June 2004
Mr Brian Jamieson Non-Executive Chairman 22 November 2007
Mr Donal O'Dwyer Non-Executive Deputy Chairman,Non-Executive Director 29 September 2004
Mr Michael Robert Spooner Non-Executive Director 15 August 2005
Dr Ben-Zion Weiner Non-Executive Director 09 May 2012
Dr Eric A Rose Non-Executive Director 15 April 2013
Mr William M Burns Non-Executive Director 06 March 2014

Name Position
Charlie Harrison Company Secretary

Substantial Shareholders
Holding Name
17,600,000 (5.56%) Thorney Holdings Pty Ltd and Thorney Pty Ltd and associated entities
32,018,195 (10.11%) M&G Investment Funds
55,785,806 (17.62%) Cephalon International Holdings Inc
68,244,642 (21.56%) Silviu Itescu

Calendar of Events
Date Event
25 August 2015 Report (Prelim)
25 February 2015 Report (Interim)
20 November 2014 AGM
10 October 2014 Report (Annual)
© 2011 Morningstar, Inc. All rights reserved. The data and content contained herein are not guaranteed to be accurate, complete or timely. Neither Morningstar, nor its affiliates nor their content providers will have any liability for use or distribution of any of this information. To the extent that any of the content above constitutes advice, it is general advice that has been prepared by Morningstar Australasia Pty Ltd ABN: 95 090 665 544, AFSL: 240892 (a subsidiary of Morningstar, Inc.), without reference to your objectives, financial situation or needs. Before acting on any advice, you should consider the appropriateness of the advice and we recommend you obtain financial, legal and taxation advice before making any financial investment decision. If applicable investors should obtain the relevant product disclosure statement and consider it before making any decision to invest. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). DISCLOSURE: Employees may have an interest in the securities discussed in this report. Please refer to our Financial Services Guide (FSG) for more information at


Trade Shares Online from $19.95^
Free Guides

The SMH Guide to Investing in Art

An educational booklet with useful, practical tips to help you make better-informed decisions about investing in art.

More details...


Billionaires bankroll Ten's new direction Media Network sees digital future

The Age 19/12/2013 | Ten Network's programming ambitions will be funded by a $200 million loan guaranteed by three of its billionaire owners, as the free-to-air broadcaster declared digital was the future and pointed to early signs that its switch to an older market demographic was working.

Elders alleges $24m fraud in live cattle division

The Age 19/12/2013 | Troubled rural services group Elders is threatening to call in the police over an alleged $24 million fraud by a "handful of individuals" in its live cattle exports division.

Bega Cheese holds back in three-way bidding war for WCB

The Age 19/12/2013 | Bega Cheese began the battle for Warrnambool Cheese & Butter but three months on it appears to be the first casualty of the bidding war.

Aussie hampers transition

The Age 19/12/2013 | A persistently high Australian dollar is thwarting the Reserve Bank's efforts to ease the transition of the economy away from mining.

RBA keeps its focus on lower dollar

The Age 19/12/2013 | The Reserve Bank is keeping the door open to further interest rate cuts, but believes the "significant amount" of monetary policy easing over the past two years is already stimulating growth.

Pact's struggles weigh down Orora

The Age 19/12/2013 | The underwhelming sharemarket debut of packaging company Pact Group Holdings has weighed on the demerger of Amcor and its $2 billion Australasian packaging and distribution business Orora.


Sponsored Links